Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > January 9, 2024
Daily News
January 9, 2024
- BioCryst Japan to First Focus on Orladeyo Promotion, Eager to Set Up Own Sales Team: Local Head
January 9, 2024
- FPMAJ Stands Firmly Against Full Implementation of Off-Year Price Revision in FY2025
January 9, 2024
- Santen, Astellas, 3 More Firms Hit by Manufacturing Delays after Quake
January 9, 2024
- Organon Japan Gets Approval for Fertility Med Follistim after Re-Filing
January 9, 2024
- Trelegy Frontrunner in GP Promotion, Dayvigo Defends Title in HP List in October: Intage
January 9, 2024
- Boehringer Grabs Rights to Kyowa Kirin’s Fibro-Inflammatory Disease Drug
January 9, 2024
- US FDA Accepts Stelara Biosimilar for Review: Meiji
January 9, 2024
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…